Four-year clinical and echocardiographic outcomes of the Myval device in mitral, tricuspid, and pulmonary positions
Introduction and objectives: Transcatheter implantation of balloon-expandable valves in non-aortic positions represents a growing off-label strategy for valve-in-valve and valve-in-ring procedures in high-risk patients. We assessed 4-year clinical outcomes and echocardiographic performance of the transcatheter heart valve Myval THV implanted in the mitral, tricuspid, and pulmonary positions. Methods: This retrospective multicenter study included a total of 50 patients (mitral n = 33; tricuspid n = 13; pulmonary n = 4) treated across 11 centers, with clinical follow-up extending to 4 years and echocardiographic assessment of surviving patients. Results: Technical successs was achieved in 96.9% of mitral cases (1 procedural death) and in 100% of tricuspid and pulmonary cases. At 1 year, death had occurred in 2/33 (6.1%) mitral patients and in none of the tricuspid or pulmonary patients. At 4 years, death had occurred in 4/33 (12.1%) mitral, 2/13 (15.3%) tricuspid, and 0/4 pulmonary patients; stroke occurred in 0/33, 1/13 (7.6%), and 0/4 patients, respectively. Mean transvalvular gradients at 4 years were 8.5 ± 3.3 mmHg (mitral), 3.8 ± 1.6 mmHg (tricuspid), and 12.7 ± 9.9 mmHg (pulmonary). No moderate or greater bioprosthetic regurgitation was observed at 4-year echocardiographic assessment, and no valve reinterventions were recorded during follow-up. Conclusions: In this multicenter cohort, off-label use of the Myval THV in non-aortic positions demonstrated adequate midterm clinical outcomes and sustained echocardiographic performance up to 4 years. These preliminary findings support the feasibility of this transcatheter approach in selected patients but require further prospective validation.
Authors
- Filippo Pensotti (ORCID: https://orcid.org/0000-0002-7608-1025)
- Krešimir Štambuk (ORCID: https://orcid.org/0000-0002-9107-6187)
- Henrik Nissen (ORCID: https://orcid.org/0000-0002-0842-3644)
- Manuel Carrasco‐Moraleja (ORCID: https://orcid.org/0000-0002-7282-2367)
- Sengottuvelu Gunasekaran (ORCID: https://orcid.org/0000-0001-5339-6449)
- Marcelo Rodríguez Murillo
- Ashok Seth (ORCID: https://orcid.org/0000-0001-6883-0287)
- Mauricio Zúñiga
- Carlos Cortés (ORCID: https://orcid.org/0000-0002-2298-6646)
- Mathias Dyreborg Jørgensen (ORCID: https://orcid.org/0009-0004-9830-1502)
- A. Jurado Román
- Silvia Vallinas‐Hernández
- Akash Jain
- Pedro Martin
- JOHN JOSE
- Matteo Montorfano
- Marcio Montenegro da Costa
- Phillip Freeman
- Mussayev Abdurashid
- Ignacio J. Amat-Santos
- Mario García-Gómez
- Cristhian Aristizabal
Institutions
- Apollo Hospitals (IN)
- Vita-Salute San Raffaele University (IT)
- Christian Medical College, Vellore (IN)
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- San Raffaele University of Rome (IT)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Fortis Escorts Heart Institute (IN)
- Christian Medical College (IN)
- Apollo Hospitals (IN)
- Astana Medical University (KZ)
- Hospital Clínico Universitario de Valladolid (ES)
Publication Details
- Journal
- REC interventional cardiology (English Edition)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.24875/recice.m26000632
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00